neurology

News

Roche's SMA drug gets PRIME regulatory status in Europe

Roche is hoping to challenge Biogen with a new treatment for the rare muscle wasting disease spinal muscular atrophy – and the plans just got a boost after European regulators gave it speci

News

Closeup of X-ray photography of human brain

Lilly focuses on tau with AC Immune Alzheimer's R&D tie-up

Eli Lilly has paid $81m to develop drugs targeting aggregation of tau proteins associated with Alzheimer’s with Swiss biotech AC Immune, as focus shifts away from therapies targeting clumps

News

Illustration of a nerve cell on a colored background with light effects

Neurocrine slumps as Tourette's drug fails clinical trial

Shares in Neurocrine Biosciences slumped by as much as a fifth after a much-anticipated trial in Tourette’s syndrome missed the mark.

News

GW launches cannabis-based epilepsy drug in US

GW Pharmaceuticals is bullish about the company’s prospects following the launch of its cannabis-based medicine for a rare form of childhood epilepsy.

News

Akili gains rights to UCSF therapeutic video game

Digital health firm Akili has struck a deal with the University of California, giving it exclusive rights to a therapeutic video game that could improve cognitive function in psychological

News

Lundbeck brings third Parkinson's drug into clinic

Denmark’s Lundbeck is bringing a third potential drug for Parkinson’s disease to the clinic – a human antibody that the company hopes will tackle the underlying cause of the condition.

Roche's SMA drug gets PRIME regulatory status in Europe

Lilly focuses on tau with AC Immune Alzheimer's R&D tie-up

Neurocrine slumps as Tourette's drug fails clinical trial

GW launches cannabis-based epilepsy drug in US

Akili gains rights to UCSF therapeutic video game

Lundbeck brings third Parkinson's drug into clinic

ADARx, Trex, and Retension take aim at IPOs

Discover a new era of healthcare panel engagement: Grounded ...

neurology

Editor's Picks